Limited Japan Nod For Cytori’s Osteoarthritis Cell Therapy

Japan's well-defined regulatory framework for cell and regenerative therapies has notched up another "win" with the limited-use approval of a product for knee osteoarthritis, which should also generate useful new revenues for originator Cytori.